Johnson & Johnson Push Ahead With Invega Franchise
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm files response to “complete response” letter for once-monthly version and tries for new indication for once-daily paliperidone.
You may also be interested in...
FDA To Centocor: Show Me The REMS
Ustekinumab “complete response” letter requests medication guide and communication plan, but not restricted distribution.
Paliperidone Palmitate Launch Unlikely Until 2010, J&J Says
New dosing option for the atypical antipsychotic will be included in the NDA resubmission.
J&J Cautious On Paliperidone Palmitate
Could management’s lack of enthusiasm for the schizophrenia drug foreshadow a delay at FDA?
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: